A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
Sanjay Popat, Alessandra Curioni‐Fontecedro, Urania Dafni, R. Shah, Mary O’Brien, A. Pope, P.M. Fisher, James Spicer, A. Roy, David Gilligan, Oliver Gautschi, Ernest Nadal, Wolf-Dieter Janthur, Rafael López Castro, Rosario García Campelo, Sylvie Rusakiewicz, Igor Letovanec, Varvara Polydoropoulou, Heidi Roschitzki‐Voser, Barbara Ruepp, A. Gasca-Ruchti, Solange Peters, Rolf A. Stahel
Topics & Concepts
MedicinePembrolizumabInternal medicineOncologyChemotherapyGemcitabineTolerabilityClinical endpointPemetrexedProgression-free survivalResponse Evaluation Criteria in Solid TumorsPhases of clinical researchSurgeryClinical trialImmunotherapyAdverse effectCancerCisplatinOccupational and environmental lung diseasesCancer Immunotherapy and BiomarkersPleural and Pulmonary Diseases